Barclays reiterated an Overweight rating and $209 price target on Sarepta (SRPT) after the company reported a patient death post treatment of ...

Dystrophin helps keep muscles intact and functional.William Blair's Corwin noted two patients died following treatment with Novartis' Zolgensma, a treatment for spinal muscular atrophy."Overall, we ...

BofA Securities analyst Jason Kupferberg said the decline in Affirm Holdings (AFRM) stock after a new Walmart/Klarna ...

Advanced Micro Devices (AMD) has had a rough year. The stock has taken a 55% beating since peaking last year, weighed down by ...

Mizuho slashes its price target on shares of the cryptocurrency exchange but still sees some upside after a recent 30% drop.

Tariff-fueled recession fears that have rocked stocks in March don't appear to be damaging higher-income consumers' desire to ...

Wall Street's biggest bull explains why Tesla investors are getting too overwrought by concerns over Elon Musk's close ties ...

While competition could affect margins, Citi believes Varun Beverages has several levers to manage this challenge.

The Street believes that the correction is overdone and that the company has multiple growth opportunities in India and the ...

Barclays analysts believe the recent selloff in cruise line stocks is overdone, arguing that the market is "implying Cruise Lines' pricing will unravel" when the reality is far more stable.